OmniAb, Inc. (OABI) AI Stock Analysis

OmniAb, Inc., founded in 2012 and based in Emeryville, California, specializes in therapeutic antibody discovery technologies. Its platform grants industry partners access to diverse antibody repertoires and screening technologies to identify next-generation therapeutics. The core proprietary OmniAb platform uses genetically modified transgenic animals, including OmniRat, OmniChicken, and OmniMouse, engineered to produce antibodies with human sequences to improve efficacy and reduce immunogenicity. OmniAb also provides specialized platforms such as OmniFlic and OmniClic for bispecific antibody applications utilizing a common light chain approach, alongside OmniTaur, which leverages structural attributes from cow antibodies to target complex disease mechanisms.

OmniAb's annual revenue dropped from $59.1M in FY2022 to $18.7M in FY2025, representing a 5-year revenue CAGR of -4.3% from FY2020 through FY2025. Over that span, annual net losses deepened from -$22.3M in FY2022 to -$64.8M in FY2025, accompanied by an operating margin of -383.1% and R&D spending of $47.8M in FY2025. Performance improved over the trailing twelve months ended June 30, 2026, with revenue reaching $38.5M. In the latest quarter ended June 30, 2026, quarterly revenue grew 244.2% year-over-year, while trailing twelve-month profit margin stood at -115.1% and trailing EPS was -$0.36.

As of June 30, 2026, OmniAb held $52.0M in cash and short-term investments against $18.9M in total debt, resulting in net cash of $33.1M. The company maintains a current ratio of 4.80 and a debt-to-equity ratio of 0.07 against $260.3M in shareholders' equity. Operating cash flow was -$36.5M and free cash flow was -$37.0M in FY2025. Capital expenditures totaled $565,000 in FY2025, while the 5-year share count change was 55.9%.

OmniAb's stock closed at $4.59 on October 16, 2026, giving it a market cap of $667.3M and an enterprise value of $663.3M. The shares trade at a price-to-sales ratio of 17.4x and an EV-to-revenue ratio of 17.2x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Over the past year, the stock returned 170.0%, outperforming the S&P 500's 16.8% return, while its 5-year return sits at -54.0% versus 83.0% for the index.

Wall Street sentiment is unanimous, with 7 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell recommendations. The mean price target of $8.33 represents an 81.6% upside over the last closing price of $4.59. For the current fiscal year ending December 31, 2026, analysts forecast revenue of $35.0M and an EPS of -$0.37. For the next fiscal year, 4 analysts estimate revenue of $43.9M, representing 25.3% growth, with EPS of -$0.29. OmniAb beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is October 30, 2026.

This page is an AI-written research summary of OmniAb, Inc. (OABI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OABI income statement, OABI balance sheet, OABI key metrics, OABI analyst forecast, OABI chart. See the OABI stock overview for the latest quote and news.